Autoimmune Complications in Hematologic Neoplasms.
Barcellini W, Giannotta JA, Fattizzo B.
Cancers (Basel). 2021 Mar 26;13(7):1532. doi: 10.3390/cancers13071532.
Cryoglobulinemia.
Killeen RB, Awais M, Mikes BA.
2025 Mar 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
Multiple myeloma with concurrent immune thrombocytopenic purpura.
Sarfraz H, Anand K, Liu S, Shah S.
Ecancermedicalscience. 2020 Feb 20;14:1012. doi: 10.3332/ecancer.2020.1012. eCollection 2020.
Cryoglobulinemia.
Winfield JB.
Hum Pathol. 1983 Apr;14(4):350-4. doi: 10.1016/s0046-8177(83)80121-x.
Low dose cepharanthine ameliorates immune thrombocytopenic purpura associated with multiple myeloma.
Tabata R, Tabata C, Tazoh A, Nagai T.
Int Immunopharmacol. 2012 Jul;13(3):242-4. doi: 10.1016/j.intimp.2012.04.015. Epub 2012 May 3.
Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature.
Yao H, Zhang X, Liu J, Zhu L, Chen G, Wu S, Gao L.
Int J Clin Exp Pathol. 2015 Nov 1;8(11):15429-32. eCollection 2015.
Immune thrombocytopenia purpura associated with multiple myeloma.
Faller E, Chapman L, Enright H, Browne P, McHugh J, Desmond R.
Ann Hematol. 2016 Aug;95(8):1371-2. doi: 10.1007/s00277-016-2694-y. Epub 2016 May 13.
Daratumumab as a novel treatment option in refractory ITP.
Vernava I, Schmitt CA.
Blood Cells Mol Dis. 2023 Mar;99:102724. doi: 10.1016/j.bcmd.2023.102724. Epub 2023 Jan 13.
Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.
Qiu L, Zhu F, Wei G, Wu W, Yang L, Hu Y, Huang H.
Regen Ther. 2020 May 15;14:271-274. doi: 10.1016/j.reth.2020.03.005. eCollection 2020 Jun.
Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.
Moore H, Romeril K.
Intern Med J. 2011 Apr;41(4):348-50. doi: 10.1111/j.1445-5994.2011.02458.x.
